The vaccine adverse event reporting system and vaccine safety research in the genomics era

Vaccine

Volumn 30, Issue 6, 2012, Pages 1162-1164

  Davis, Robert Lowell ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

Genomics; Vaccine adverse events; VAERS

Indexed keywords

VACCINE;

ADVERSE OUTCOME; ARTICLE; DRUG RESEARCH; DRUG SAFETY; GENOMICS; HUMAN; PRIORITY JOURNAL; RISK FACTOR; VACCINATION; VACCINE ADVERSE EVENT REPORTING SYSTEM;

ADVERSE DRUG REACTION REPORTING SYSTEMS; GENOMICS; HUMANS; VACCINES;

EID: 84856320123     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.018     Document Type: Article

References (18)

1. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbut N.C., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765.
2. *5701 screening for hypersensitivity to abacavir. N Engl J Med 2008, 358:568-579.
3. Poland G.A., Ovsyannikova I.G., Jacobson R.M. Adversomics the emerging field of vaccine adverse event immunogenetics. Pediatr Infect Dis J 2009, 28:431-432.
4. Ball R., et al. HLA type and immune response to outer surface protein A in people in whom arthritis developed after lyme disease vaccination. Arthritis Rheum 2009, 60(April (4)):1179-1186.
5. Varricchio F., Iskander J., Destefano F., Ball R., Pless R., Braun M.M., et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004, 23:287-294.
6. Braun M.M. Toward better vaccine safety data and safer vaccination. Pediatrics 2008, 121:625-626.
7. ® meningococcal conjugate vaccine - United States, June 2005-September 2006. MMWR 2006, 55(41):1120-1124.
8. Velentgas P., Bohn R.L., Brown J.S., Chan K.A., Gladowski P., Holick C.N., et al. A distributed research network model for post-marketing safety studies: the meningococcal vaccine study. Pharmacoepidemiol Drug Saf 2008, 17:1226-1234.
9. Manolio T.A., Bailey-Wilson J.E. Collins FS Genes, environment and the value of prospective cohort studies. Nat Rev Genet 2006, 7(10):12-20.
10. Collins F.S. The case for a US prospective cohort study of genes and environment. Nature 2004, 429:475-477.
11. Chen R.T., Glasser J.W., Rhodes P.H., Davis R.L., Barlow W.E., Thompson R.S., et al. Vaccine Safety Datalink Project: a new tool for improving vaccine safety monitoring in the United States. Pediatrics 1997, 99(6):765-773.
12. Baggs J., Gee J., Lewis E., Fowler G., Benson P., Lieu T., et al. The Vaccine Safety Datalink: a model for monitoring immunization safety. Pediatrics 2011, 127(s1):s45-s53.
13. Barlow W., Davis R.L., Glasser J., Rhodes P., et al. Seizures following pertussis or measles vaccination: risks and long term outcomes. N Engl J Med 2001, 345:656-661.
14. France E.K., Glanz J., Xu S., Hambidge S., Yamasaki K., Black S.B., et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics 2008, 121:e687.
15. Manolio T.A. Genomewide association studies and assessment of the risk of disease. N Engl J Med 2010, 363:166-176.
16. Ng S.B., Turner E.H., Robertson P.D., Flygare S.D., Bigham A.W., Lee C., et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature 2009, 461:272-276.
17. Collins F.S. Implementing Personalized Medicine: Scientific and Translational Challenges. AAAS Personalized Medicine: Planning for the Future Colloquium; 2009. http://www.aaas.org/spp/PM/ppts/Collins.pdf.
18. Zhou W., Pool V., Iskander J.K., English-Bullard R., Ball R., Wise R.P., et al. Surveillance for safety after immunization; Vaccine Adverse Event Reporting System (VAERS)-United States, 1991-2001. MMWR Surveill Summ 2003, 52:1-24.